271 related articles for article (PubMed ID: 32394425)
21. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
Schaberg KB; Novoa RA; Wakelee HA; Kim J; Cheung C; Srinivas S; Kwong BY
J Cutan Pathol; 2016 Apr; 43(4):339-46. PubMed ID: 26762844
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
23. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
24. Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.
Fixsen E; Patel J; Selim MA; Kheterpal M
Oncologist; 2019 Mar; 24(3):e103-e105. PubMed ID: 30617087
[TBL] [Abstract][Full Text] [Related]
25. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
26. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
27. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
[TBL] [Abstract][Full Text] [Related]
28. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
[TBL] [Abstract][Full Text] [Related]
29. Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate.
Varma A; Friedlander P; De Moll EH; Desman G; Levitt J
Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621697
[TBL] [Abstract][Full Text] [Related]
30. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
31. Hypertrophic Lichen Planus with Histological Features of Squamous Cell Carcinoma Associated with Immune Checkpoint Blockade Therapy.
Ameri AH; Foreman RK; Vedak P; Chen S; Miller DM; Demehri S
Oncologist; 2020 May; 25(5):366-368. PubMed ID: 32073194
[TBL] [Abstract][Full Text] [Related]
32. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Takada S; Hirokazu H; Yamagishi K; Hideki S; Masayuki E
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1697-1699. PubMed ID: 32592366
[TBL] [Abstract][Full Text] [Related]
33. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
34. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
35. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.
Freites-Martinez A; Kwong BY; Rieger KE; Coit DG; Colevas AD; Lacouture ME
JAMA Dermatol; 2017 Jul; 153(7):694-697. PubMed ID: 28467522
[TBL] [Abstract][Full Text] [Related]
36. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer.
Diaz-Perez JA; Beveridge MG; Victor TA; Cibull TL
J Cutan Pathol; 2018 Jun; 45(6):434-438. PubMed ID: 29468713
[TBL] [Abstract][Full Text] [Related]
37. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
Chen WS; Tetzlaff MT; Diwan H; Jahan-Tigh R; Diab A; Nelson K; Glitza IC; Kaunitz GJ; Johnson D; Torres-Cabala C; Pacha O; Taube JM; Maloney K; Prieto VG; Curry JL
J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
[TBL] [Abstract][Full Text] [Related]
38. Vascular variant of keratosis lichenoides chronica associated with hypothyroidism and response to tacalcitol and acitretin.
Nijsten T; Mentens G; Lambert J
Acta Derm Venereol; 2002; 82(2):128-30. PubMed ID: 12125942
[TBL] [Abstract][Full Text] [Related]
39. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
Shazib MA; Woo SB; Sroussi H; Carvo I; Treister N; Farag A; Schoenfeld J; Haddad R; LeBoeuf N; Villa A
Oral Dis; 2020 Mar; 26(2):325-333. PubMed ID: 31642136
[TBL] [Abstract][Full Text] [Related]
40. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
